J Guidi1, G A Fava, M Fava, G I Papakostas. 1. Affective Disorders Program, Department of Psychology, University of Bologna, Italy. jenny.guidi2@unibo.it
Abstract
BACKGROUND: Prevention of relapse and recurrence represents an important task in the successful treatment of major depressive disorder (MDD). The aim of this meta-analysis was to examine the efficacy of the sequential integration of psychotherapy and pharmacotherapy in reducing the risk of relapse and recurrence in MDD. METHOD: Keyword searches were conducted in Medline, EMBASE, PsycINFO and the Cochrane Library from inception of each database to December 2008. Randomized controlled trials examining the efficacy of the administration of psychotherapy after successful response to acute-phase pharmacotherapy in the treatment of adults with MDD were considered for inclusion in the meta-analysis. RESULTS: Eight high-quality studies with 442 patients in a sequential treatment arm and 433 in a control treatment arm were included. The pooled risk ratio (RR) for relapse/recurrence was 0.797 [95% confidence interval (CI) 0.659-0.964] according to the random-effects model, suggesting a relative advantage in preventing relapse/recurrence for the sequential administration of treatments compared with control conditions. Performing subgroup analyses, we found a trend favoring psychotherapy during continuation of antidepressant drugs compared to antidepressants or treatment as usual (RR 0.842, 95% CI 0.674-1.051). Patients randomized to psychotherapy while antidepressants were discontinued were significantly less likely to experience relapse/recurrence compared to controls (RR 0.650, 95% CI 0.463-0.912). CONCLUSIONS: We found evidence that the sequential integration of psychotherapy and pharmacotherapy is a viable strategy for preventing relapse and recurrence in MDD. In addition, our findings suggest that discontinuation of antidepressant drugs may be feasible when psychotherapy is provided.
BACKGROUND: Prevention of relapse and recurrence represents an important task in the successful treatment of major depressive disorder (MDD). The aim of this meta-analysis was to examine the efficacy of the sequential integration of psychotherapy and pharmacotherapy in reducing the risk of relapse and recurrence in MDD. METHOD: Keyword searches were conducted in Medline, EMBASE, PsycINFO and the Cochrane Library from inception of each database to December 2008. Randomized controlled trials examining the efficacy of the administration of psychotherapy after successful response to acute-phase pharmacotherapy in the treatment of adults with MDD were considered for inclusion in the meta-analysis. RESULTS: Eight high-quality studies with 442 patients in a sequential treatment arm and 433 in a control treatment arm were included. The pooled risk ratio (RR) for relapse/recurrence was 0.797 [95% confidence interval (CI) 0.659-0.964] according to the random-effects model, suggesting a relative advantage in preventing relapse/recurrence for the sequential administration of treatments compared with control conditions. Performing subgroup analyses, we found a trend favoring psychotherapy during continuation of antidepressant drugs compared to antidepressants or treatment as usual (RR 0.842, 95% CI 0.674-1.051). Patients randomized to psychotherapy while antidepressants were discontinued were significantly less likely to experience relapse/recurrence compared to controls (RR 0.650, 95% CI 0.463-0.912). CONCLUSIONS: We found evidence that the sequential integration of psychotherapy and pharmacotherapy is a viable strategy for preventing relapse and recurrence in MDD. In addition, our findings suggest that discontinuation of antidepressant drugs may be feasible when psychotherapy is provided.
Authors: Amy Farabaugh; Jonathan Alpert; Stephen R Wisniewski; Michael W Otto; Maurizio Fava; Lee Baer; Roy Perlis; Ed Friedman; Maren Nyer; Stella Bitran; G K Balasubramani; Aya Inamori; Madhukar Trivedi; Michael E Thase Journal: J Affect Disord Date: 2012-08-09 Impact factor: 4.839
Authors: Sagar V Parikh; Lena C Quilty; Paula Ravitz; Michael Rosenbluth; Barbara Pavlova; Sophie Grigoriadis; Vytas Velyvis; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Jan Philipp Klein; Thomas Berger; Johanna Schröder; Christina Späth; Björn Meyer; Franz Caspar; Wolfgang Lutz; Alice Arndt; Wolfgang Greiner; Viola Gräfe; Martin Hautzinger; Kristina Fuhr; Matthias Rose; Sandra Nolte; Bernd Löwe; Gerhard Anderssoni; Eik Vettorazzi; Steffen Moritz; Fritz Hohagen Journal: Psychother Psychosom Date: 2016-05-27 Impact factor: 17.659
Authors: Betsy D Kennard; Graham J Emslie; Taryn L Mayes; Paul A Nakonezny; Jessica M Jones; Aleksandra A Foxwell; Jessica King Journal: Am J Psychiatry Date: 2014-10 Impact factor: 18.112
Authors: Willoughby B Britton; Patricia L Haynes; Keith W Fridel; Richard R Bootzin Journal: Psychother Psychosom Date: 2012-07-20 Impact factor: 17.659
Authors: Paul M G Emmelkamp; Daniel David; Tom Beckers; Peter Muris; Pim Cuijpers; Wolfgang Lutz; Gerhard Andersson; Ricardo Araya; Rosa M Banos Rivera; Michael Barkham; Matthias Berking; Thomas Berger; Christina Botella; Per Carlbring; Francesc Colom; Cecilia Essau; Dirk Hermans; Stefan G Hofmann; Susanne Knappe; Thomas H Ollendick; Filip Raes; Winfried Rief; Heleen Riper; Saskia Van Der Oord; Bram Vervliet Journal: Int J Methods Psychiatr Res Date: 2014-01 Impact factor: 4.035
Authors: Margo de Jonge; Claudi L H Bockting; Martijn J Kikkert; Judith E Bosmans; Jack J M Dekker Journal: BMC Psychiatry Date: 2015-07-01 Impact factor: 3.630